Zhejiang Shapuaisi Pharmaceutical Co. Ltd. (603168.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.6x

Market Cap

CNY 2.07B

MomentumView details →

1D Return

−0.72%

YTD Return

−20.38%

RSI (14)

59.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.6x

Market Cap

CNY 2.07B

RSI (14)

59.1

MomentumView details →

1D Return

−0.72%

YTD Return

−20.38%

ProfitabilityView details →

Gross Margin

44.33%

Net Margin

−59.55%

EBITDA Margin

−37.70%

ROE (TTM)

−20.65%

ROA (TTM)

−15.45%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+2.62%

EPS YoY

—

FCF YoY

+7.55%

Revenue CAGR 3Y

−5.57%

EPS CAGR 3Y

−93.94%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

0.89x

Quick Ratio

0.62x

Div Yield

—

Div Rate

—

Div Growth 1Y

−43.24%

Financials snapshotView financials →

Revenue (TTM)

459.57M

Net Income (TTM)

−273.68M

Op. CF (TTM)

26.49M

Latest newsMore news →

Shapuaisi announced its first-half 2026 results with revenue of 197 million yuan, down 16.77% year-on-year, and net profit attributable to shareholders of 19.5 million yuan, down 10.81% year-on-year.7d ago

Similar companies

汉商集团600774.SH ST葫芦娃605199.SH 第一医药600833.SH Shanghai Pioneer Holding Ltd01345.HK 健之佳605266.SH 国发股份600538.SH Find similar companies →

Latest newsMore news →

Shapuaisi announced its first-half 2026 results with revenue of 197 million yuan, down 16.77% year-on-year, and net profit attributable to shareholders of 19.5 million yuan, down 10.81% year-on-year.7d ago